2023 Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes - Enduring Recorded Webcast

This accredited continuing education activity “Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes” is recorded from the live conference held from 8/04/2023 to 8/05/2023.

If you participated in the course titled - Seattle Cellular Therapy Summit (SCTS): Patient-Centered Approach to Improve Outcomes from 8/04/2023 to 08/05/2023 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is recorded content from that course from 8/04/2023 to 08/05/2023. However, you can still enroll in this activity and review the contents as needed.

This recorded webcast, “Seattle Cellular Therapy Summit (SCTS): Patient-Centered Approach to Improve Outcomes,” features leading experts in hematologic malignancies and cellular therapies who will provide a comprehensive overview of current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular therapies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies and to describe potential future applications of cellular therapy in solid tumors. The activity uses a mix of didactic lectures and case-based discussions to highlight areas of debate between cellular therapy and non-cellular therapy in the treatment of these diseases. Expert faculty place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. 

The symposium augments healthcare providers’ foundation of knowledge and clinical competence in several areas:

  • Providing a review of existing clinical evidence supporting approved Chimeric Antigen Receptor T-cell (CAR T) therapies in the care of patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM)
  • Describing the role of non-cellular therapies in B-ALL, DLBCL, FL, MCL, and MM
  • Identifying challenges to the delivery of cellular therapies and provide a discussion on how such barriers may be addressed
  • Discussing novel investigational approaches of cellular therapy in acute myeloid leukemias and solid tumors

REGISTRATION FEES:

This activity is free for all. 

Target Audience

  • Hematologists/Medical Oncologists 
  • Oncology fellows
  • Oncology nurses
  • NPs/PAs
  • Oncology pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review indications and outcomes of approved cellular therapies in hematologic malignancies
  • Identify emerging CAR-based therapies in hematologic malignancies and solid tumors
  • Identify and manage complications after cellular therapy
  • Incorporate into practice knowledge about financial toxicity and quality of life after CAR T-cell therapies
  • State the financial, physical, and other barriers, review strategies to navigate these factors to optimize the management of patients with cellular therapies

You may also be interested in

2023 Summit on Cancer Health Disparities- Recorded Webcast

This accredited continuing education activity “2023 Summit on Cancer Health Disparities”, was recorded from the live course held on 04/28/23-04/30/23
Course summary
Available credit: 
  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.
Course opens: 
08/30/2023
Course expires: 
08/04/2024
Cost:
$0.00

 

This educational activity features recorded videos from the meeting titled "Seattle Cellular Therapy Summit (SCTS): Patient-Centered Approach to Improve Outcomes" held from 08/04/2023 to 08/05/2023.

The videos are placed in the following order. Feel free to view the content that is relevant to you.

Participants should claim continuing education credits to the extent of their participation.

Conference Co-Chairs: Dr. Krish Patel and Dr. Mazyar Shadman

SESSION 1 - UPDATES ON APPROVED CAR T-CELL THERAPIES       

25 Minutes: Updates in CAR T-Cell Therapy in Lymphoma - David Maloney, MD, PhD

25 Minutes: Updates in CAR T-Cell Therapy in Myeloma - Andrew Cowan, MD

30 Minutes: Updates in CAR T-Cell Therapy in ALL - Richard Maziarz, MD

30 Minutes: Panel Discussion with David Aboulafia, MD; Andrew Cowan, MD; Krishna Komanduri, MD; Yi Lin, MD, PhD; Krish Patel, MD; and Mazyar Shadman, MD, MPH 

SESSION 2 - DEBATES IN DLBCL AND FL

5 Minutes: Case Presentation: Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Emily Liang, MD

10 Minutes: DLBCL Debate: CAR T versus Auto-HSCT versus Non-Cellular Therapy – In Favor of CAR T - Olalekan O. Oluwole, MBBS, MD

10 Minutes: DLBCL Debate: CAR T versus Auto-HSCT versus Non-Cellular Therapy – In Favor of Auto-HSCT - Mazyar Shadman, MD, MPH

10 Minutes: DLBCL Debate: CAR T versus Auto-HSCT versus Non-Cellular Therapy – In Favor of Non-cellular Therapy - Tycel Phillips, MD

20 Minutes: Discussion

5 Minutes: Case Presentation: Relapsed/Refractory Follicular Lymphoma (FL) - Laura Samples, MD

15 Minutes: FL Debate: CAR T versus Mosun versus Other – In Favor of CAR T - Matthew Ulrickson, MD

10 Minutes: FL Debate: CAR T versus Mosun versus Other – In Favor of Mosun - Nadia Khan, MD

10 Minutes: FL Debate: CAR T versus Mosun versus Other – In Favor of Other - Chaitra Ujjani, MD

15 Minutes: Discussion

SESSION 3 - DEBATES IN MCL AND MYELOMA

5 Minutes: Case Presentation: Relapsed/Refractory Mantle Cell Lymphoma (MCL) - Julia Parker DRNP, AGNP-C

20 Minutes: MCL Debate: CAR T versus BTKi – In Favor of CAR T - Matt Lunning, DO

15 Minutes: MCL Debate: CAR T versus BTKi – In Favor of BTKi - Alexey Danilov, MD

20 Minutes: Discussion 

10 Minutes: Case Presentation: Relapsed/Refractory Multiple Myeloma (MM) - Josh Epworth, ARNP

15 Minutes: Myeloma Debate: CAR T versus Teclistimab – In Favor of CAR T - Swathi Namburi, MD

15 Minutes: Myeloma Debate: CAR T versus Teclistimab – In Favor of Teclistimab - Rahul Banerjee, MD

15 Minutes: Discussion 

SESSION 4 - ADDRESSING BARRIERS TO CELLULAR THERAPY

10 Minutes: Case Presentation: Patient Barriers to Cellular Therapy - Sonia Glennie, ARNP, MSN, OCN and Samuel Jonas, MSW

15 Minutes: Allogeneic Cell Therapy: Glimpse of the Future? - Krish Patel, MD

20 Minutes: Panel Discussion with David Aboulafia, MD; Matt Lunning, DO; and Krish Patel, MD

SESSION 5 - CELLULAR THERAPY IN LEUKEMIAS

15 Minutes: Bispecific Antibody and CAR T Therapy in ALL - What is the right sequence? - Ryan Cassaday, MD

15 Minutes: CAR T Cell therapy in CLL - Tanya Siddiqi, MD

15 Minutes: Cellular Therapy in AML/MDS: Emerging Data - Hany Elmariah, MD

20 Minutes: Cellular Therapy in AML: Overcoming Challenges - Naval Daver, MD

15 Minutes: Discussion

SESSION 6: CELLULAR THERAPY IN SOLID TUMORS

15 Minutes: Cellular Therapy in Solid Tumors: Emerging Data - Kedar Kirtane, MD

15 Minutes: Cellular Therapy in Solid Tumors: Overcoming Challenges - Kelly Paulson, MD, PhD

20 Minutes: Discussion

 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

COURSE DIRECTOR(S)

Krish Patel, MD has a financial relationship (Professional Services) with Abbvie; financial relationship (Professional Services) with Epizyme; financial relationship (Professional Services) with Janssen/Pharmacyclics; financial relationship (Professional Services) with Xencor; financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Caribou; financial relationship (Professional Services) with Kite; financial relationship (Professional Services) with ADC Therapeutics; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Pfizer; financial relationship (Professional Services) with BeiGene; financial relationship (Professional Services) with Fate Therapeutics; financial relationship (Professional Services) with Lilly.

Mazyar Shadman, MD,MPH has a financial relationship (Professional Services) with Pharmacyclics; financial relationship (Professional Services) with BeiGene; financial relationship (Employment) with BMS; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with TG Therapeutics; financial relationship (Professional Services) with MorphoSys/Incyte; financial relationship (Professional Services) with Mustang Bio ; financial relationship (Professional Services) with AbbVie; financial relationship (Professional Services) with Genmab; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with AstraZeneca.

Binay Shah, MD, MHA has no relevant financial relationships to disclose at this time.

MODERATOR(S)

David Aboulafia, MD has no relevant financial relationships to disclose at this time.

Siddhartha Devarakonda, MBBS, MD has a financial relationship (Other) with Genetech; financial relationship (Other) with AZ; financial relationship (Other) with Jazz; financial relationship (Other) with Merus.

Nadia Khan, MD has a financial relationship (Independent contractor) with Adaptive; financial relationship (Independent contractor) with PCYC; financial relationship (Independent contractor) with Beigene .

Krishna Komanduri, MD has a financial relationship (Independent contractor) with Iovance; financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with Novartis; financial relationship (Independent contractor) with Cargo Therapeutics; financial relationship (Independent contractor) with Avacta Therapeutics; financial relationship (Independent contractor) with CRISPR Therapeutics; financial relationship (Independent contractor) with Roche; financial relationship (Independent contractor) with Optum Health; financial relationship (Independent contractor) with Incyte.

Yi Lin  has a financial relationship (Grant Or Contract) with Takeda; financial relationship (Other) with Juno/BMS; financial relationship (Other) with Gamida Cells; financial relationship (Other) with Fosun Kite; financial relationship (Grant Or Contract) with BlueBird Bio; financial relationship (Other) with NexImmune; financial relationship (Other) with Celgene/BMS; financial relationship (Other) with Legend BioTech; financial relationship (Other) with Takeda; financial relationship (Grant Or Contract) with Celgene/BMS; financial relationship (Other) with Sorrento; financial relationship (Grant Or Contract) with Merck; financial relationship (Other) with Kite/Gilead; financial relationship (Other) with Janssen; financial relationship (Other) with Iovance; financial relationship (Grant Or Contract) with Kite/Gilead; financial relationship (Other) with Caribou; financial relationship (Grant Or Contract) with Legend BioTech; financial relationship (Grant Or Contract) with Boston Scientific; financial relationship (Other) with BlueBird Bio; financial relationship (Other) with Novartis; financial relationship (Other) with Pfizer; financial relationship (Grant Or Contract) with Janssen.

Matthew Lunning, Matt Lunning, D.O., F.A.C.P. has a financial relationship (Professional Services) with Morphosys; financial relationship (Professional Services) with Regeneron; financial relationship (Professional Services) with TG Therapeutics; financial relationship (Professional Services) with AbbVie; financial relationship (Professional Services) with Astellas; financial relationship (Grant Or Contract) with Curis; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with Miltenyi; financial relationship (Professional Services) with Pharmacyclics; financial relationship (Professional Services) with Takeda; financial relationship (Professional Services) with Astra Zeneca; financial relationship (Professional Services) with CRISPR; financial relationship (Professional Services) with Fate Therapeutics; financial relationship (Professional Services) with Ipsen; financial relationship (Professional Services) with Nurix; financial relationship (Professional Services) with SeaGen; financial relationship (Professional Services) with ADC Therapeutics; financial relationship (Professional Services) with Caribou; financial relationship (Professional Services) with EUSA; financial relationship (Professional Services) with InstilBio; financial relationship (Professional Services) with Loxo; financial relationship (Professional Services) with Novartis; financial relationship (Professional Services) with Sanofi; financial relationship (Professional Services) with Acrotech; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Daiichi Sankyo; financial relationship (Professional Services) with GenMab; financial relationship (Professional Services) with Kite.

Richard Maziarz, MD has a financial relationship (Independent contractor) with Kite; financial relationship (Grant Or Contract) with Gamida; financial relationship (Independent contractor) with Novartis; financial relationship (Grant Or Contract) with Orca Biotech; financial relationship (Patent) with Athersys; financial relationship (Independent contractor) with Artiva; financial relationship (Independent contractor) with Century Therapeutics; financial relationship (Independent contractor) with Allovir; financial relationship (Independent contractor) with Vor Pharma.

Krish Patel, MD has a financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Pfizer; financial relationship (Professional Services) with BeiGene; financial relationship (Professional Services) with Fate Therapeutics; financial relationship (Professional Services) with Lilly; financial relationship (Professional Services) with Epizyme; financial relationship (Professional Services) with Janssen/Pharmacyclics; financial relationship (Professional Services) with Xencor; financial relationship (Professional Services) with Abbvie; financial relationship (Professional Services) with Caribou; financial relationship (Professional Services) with Kite; financial relationship (Professional Services) with ADC Therapeutics; financial relationship (Professional Services) with AstraZeneca.

Mazyar Shadman, MD,MPH has a financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with AstraZeneca; financial relationship (Employment) with BMS; financial relationship (Professional Services) with Pharmacyclics; financial relationship (Professional Services) with BeiGene; financial relationship (Professional Services) with MorphoSys/Incyte; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with TG Therapeutics; financial relationship (Professional Services) with Genmab; financial relationship (Professional Services) with Mustang Bio ; financial relationship (Professional Services) with AbbVie.

Melody Smith, MD, MS has a financial relationship (Professional Services) with BMS; financial relationship (Stock Options) with A28 Therapeutics; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with Novartis.

PEER REVIEWER(S)

Binay Shah, MD, MHA has no relevant financial relationships to disclose at this time.

SPEAKER(S)

David Aboulafia, MD has no relevant financial relationships to disclose at this time.

Rahul Banerjee, MD, FACP has a financial relationship (Independent contractor) with SparkCures; financial relationship (Independent contractor) with Genentech/Roche; financial relationship (Grant Or Contract) with i3 Health; financial relationship (Independent contractor) with Clearview Healthcare Partners; financial relationship (Grant Or Contract) with Clinical Care Options; financial relationship (Independent contractor) with Guidepoint Global; financial relationship (Grant Or Contract) with Pack Health; financial relationship (Grant Or Contract) with Curio Science; financial relationship (Independent contractor) with Sanofi Pasteur; financial relationship (Independent contractor) with Janssen Oncology.

Ryan Cassaday, MD has a financial relationship (Grant Or Contract) with Amgen; financial relationship (Grant Or Contract) with Incyte; financial relationship (Independent contractor) with Kite; financial relationship (Stock Options) with Seagen; financial relationship (Grant Or Contract) with Servier; financial relationship (Independent contractor) with Jazz; financial relationship (Employment) with Seagen; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Independent contractor) with Amgen; financial relationship (Other) with Autolus; financial relationship (Grant Or Contract) with Kite; financial relationship (Grant Or Contract) with Vanda; financial relationship (Independent contractor) with Pfizer.

Andrew Cowan, MD has a financial relationship (Independent contractor) with Abbvie; financial relationship (Independent contractor) with BMS.

Alexey Danilov, MD, PhD has a financial relationship (Independent contractor) with Astra Zeneca; financial relationship (Independent contractor) with Lilly; financial relationship (Grant Or Contract) with Nurix; financial relationship (Independent contractor) with Beigene; financial relationship (Grant Or Contract) with Bayer; financial relationship (Grant Or Contract) with MEI; financial relationship (Independent contractor) with Abbvie.

Naval Daver, MD has a financial relationship (Other) with Amgen; financial relationship (Other) with Jazz; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Other) with Agios; financial relationship (Grant Or Contract) with Astellas; financial relationship (Grant Or Contract) with Trillium; financial relationship (Grant Or Contract) with Novimmune; financial relationship (Other) with Bristol-Meyers Squibb; financial relationship (Other) with Genentech; financial relationship (Other) with Novartis; financial relationship (Grant Or Contract) with Bristol-Meyers Squibb; financial relationship (Other) with Shattuck Labs; financial relationship (Grant Or Contract) with Genentech; financial relationship (Grant Or Contract) with Amgen; financial relationship (Grant Or Contract) with FATE Therapeutics; financial relationship (Other) with Daiichi-Sankyo; financial relationship (Other) with Servier; financial relationship (Other) with Immunogen; financial relationship (Other) with Arog; financial relationship (Grant Or Contract) with Daiichi-Sankyo; financial relationship (Other) with Syndax; financial relationship (Grant Or Contract) with Servier; financial relationship (Other) with Stemline/Menarini; financial relationship (Grant Or Contract) with Immunogen; financial relationship (Grant Or Contract) with Trovagene; financial relationship (Grant Or Contract) with KITE; financial relationship (Other) with Gilead; financial relationship (Other) with Abbvie; financial relationship (Other) with Trillium; financial relationship (Other) with Celgene; financial relationship (Grant Or Contract) with Gilead; financial relationship (Other) with KITE; financial relationship (Grant Or Contract) with Abbvie; financial relationship (Grant Or Contract) with Hanmi; financial relationship (Grant Or Contract) with Glycomimmetics; financial relationship (Other) with Pfizer; financial relationship (Other) with Astellas.

Hany Elmariah, MD, MS has a financial relationship (Grant Or Contract) with Bristol Myers Squibb.

Joshua Epworth, MSN, ARNP has no relevant financial relationships to disclose at this time.

Sonia Glennie has a financial relationship (Independent contractor) with SeaGen; financial relationship (Independent contractor) with AstraZeneca; financial relationship (Independent contractor) with Genmab; financial relationship (Independent contractor) with Janssen/PCYC.

Samuel Jonas, MSW has no relevant financial relationships to disclose at this time.

Nadia Khan, MD has a financial relationship (Independent contractor) with Beigene; financial relationship (Independent contractor) with Adaptive; financial relationship (Independent contractor) with PCYC.

Kedar Kirtane, MD has a financial relationship (Travel) with A2Bio Therapeutics; financial relationship (Stock) with Shockwave Medical; financial relationship (Stock) with Oncternal Therapeutics; financial relationship (Stock) with Seattle Genetics.

Krishna Komanduri, MD has a financial relationship (Independent contractor) with Novartis; financial relationship (Independent contractor) with Cargo Therapeutics; financial relationship (Independent contractor) with Avacta Therapeutics; financial relationship (Independent contractor) with CRISPR Therapeutics; financial relationship (Independent contractor) with Roche; financial relationship (Independent contractor) with Optum Health; financial relationship (Independent contractor) with Incyte; financial relationship (Independent contractor) with Iovance; financial relationship (Independent contractor) with Janssen.

Emily Liang, MD has no relevant financial relationships to disclose at this time.

Yi Lin has a financial relationship (Grant Or Contract) with Janssen; financial relationship (Grant Or Contract) with Boston Scientific; financial relationship (Other) with BlueBird Bio; financial relationship (Other) with Novartis; financial relationship (Other) with Pfizer; financial relationship (Grant Or Contract) with BlueBird Bio; financial relationship (Grant Or Contract) with Takeda; financial relationship (Other) with Juno/BMS; financial relationship (Other) with Gamida Cells; financial relationship (Other) with Fosun Kite; financial relationship (Other) with NexImmune; financial relationship (Grant Or Contract) with Merck; financial relationship (Other) with Celgene/BMS; financial relationship (Other) with Legend BioTech; financial relationship (Other) with Takeda; financial relationship (Other) with Sorrento; financial relationship (Grant Or Contract) with Celgene/BMS; financial relationship (Grant Or Contract) with Legend BioTech; financial relationship (Other) with Kite/Gilead; financial relationship (Other) with Janssen; financial relationship (Other) with Iovance; financial relationship (Other) with Caribou; financial relationship (Grant Or Contract) with Kite/Gilead.

Matthew Lunning, Matt Lunning, D.O., F.A.C.P. has a financial relationship (Professional Services) with Miltenyi; financial relationship (Professional Services) with Pharmacyclics; financial relationship (Professional Services) with Takeda; financial relationship (Professional Services) with Astra Zeneca; financial relationship (Professional Services) with CRISPR; financial relationship (Professional Services) with Fate Therapetuics; financial relationship (Professional Services) with Ipsen; financial relationship (Professional Services) with Nurix; financial relationship (Professional Services) with SeaGen; financial relationship (Professional Services) with ADC Therapeutics; financial relationship (Professional Services) with Caribou; financial relationship (Professional Services) with EUSA; financial relationship (Professional Services) with InstilBio; financial relationship (Professional Services) with Loxo; financial relationship (Professional Services) with Novartis; financial relationship (Professional Services) with Sanofi; financial relationship (Professional Services) with Acrotech; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Daiichi Sankyo; financial relationship (Professional Services) with GenMab; financial relationship (Professional Services) with Kite; financial relationship (Professional Services) with Morphosys; financial relationship (Professional Services) with Regeneron; financial relationship (Professional Services) with TG Therapeutics; financial relationship (Professional Services) with AbbVie; financial relationship (Professional Services) with Astellas; financial relationship (Grant Or Contract) with Curis; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Janssen.

David Maloney, MD, PhD has a financial relationship (Other) with Genentech; financial relationship (Stock Options) with A2 Biotherapeutics; financial relationship (Other) with Lilly; financial relationship (Other) with BMS; financial relationship (Grant Or Contract) with Celgene; financial relationship (Other) with Celgene; financial relationship (Other) with Kite Pharma; financial relationship (Other) with Genentech; financial relationship (Grant Or Contract) with Juno therapeutics; financial relationship (Other) with Interius; financial relationship (Patent) with Juno Therapeutics/BMS; financial relationship (Other) with Caribou Biosciences; financial relationship (Other) with Juno Therapeutics; financial relationship (Other) with Chimeric Therapeutics; financial relationship (Grant Or Contract) with Kite Pharna; financial relationship (Other) with Gilead Sciences; financial relationship (Grant Or Contract) with Bristol-Myers Squibb; financial relationship (Other) with Incyte; financial relationship (Stock Options) with Navan Technologies; financial relationship (Other) with Mustang Bio; financial relationship (Other) with ImmPACT Bio; financial relationship (Grant Or Contract) with Legend Biotech; financial relationship (Other) with Bristol-Myers Squibb.

Richard Maziarz, MD has a financial relationship (Grant Or Contract) with Orca Biotech; financial relationship (Independent contractor) with Novartis; financial relationship (Independent contractor) with Century Therapeutics; financial relationship (Patent) with Athersys; financial relationship (Independent contractor) with Artiva; financial relationship (Independent contractor) with Vor Pharma; financial relationship (Independent contractor) with Allovir; financial relationship (Grant Or Contract) with Gamida; financial relationship (Independent contractor) with Kite.

Swathi Namburi, MD has no relevant financial relationships to disclose at this time.

Olalekan Oluwole has a financial relationship (Professional Services) with Epizyme; financial relationship (Professional Services) with Cargo; financial relationship (Professional Services) with Abbvie; financial relationship (Professional Services) with Caribou; financial relationship (Professional Services) with Nektar; financial relationship (Professional Services) with Gilead; financial relationship (Professional Services) with ADC; financial relationship (Professional Services) with Kite.

Julia Parker has no relevant financial relationships to disclose at this time.

Krish Patel, MD has a financial relationship (Professional Services) with Xencor; financial relationship (Professional Services) with Abbvie; financial relationship (Professional Services) with Epizyme; financial relationship (Professional Services) with Janssen/Pharmacyclics; financial relationship (Professional Services) with ADC Therapeutics; financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Caribou; financial relationship (Professional Services) with Kite; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Pfizer; financial relationship (Professional Services) with BeiGene; financial relationship (Professional Services) with Fate Therapeutics; financial relationship (Professional Services) with Lilly.

Kelly Paulson, MD, PhD has no relevant financial relationships to disclose at this time.

Tycel Phillips, MD has a financial relationship (Independent contractor) with Genmab; financial relationship (Independent contractor) with Fencer; financial relationship (Independent contractor) with ADCT; financial relationship (Independent contractor) with BMS; financial relationship (Independent contractor) with Genentech; financial relationship (Independent contractor) with Kite; financial relationship (Independent contractor) with Abbvie; financial relationship (Independent contractor) with Beigene; financial relationship (Independent contractor) with Epizyme; financial relationship (Independent contractor) with Incite; financial relationship (Grant Or Contract) with Abbvie; financial relationship (Independent contractor) with Bayer; financial relationship (Independent contractor) with Eli Lily; financial relationship (Independent contractor) with Gilead; financial relationship (Grant Or Contract) with Genentech; financial relationship (Independent contractor) with Astra Zeneca.

Laura Samples, MD has no relevant financial relationships to disclose at this time.

Mazyar Shadman, MD,MPH has a financial relationship (Professional Services) with Mustang Bio; financial relationship (Professional Services) with AbbVie; financial relationship (Professional Services) with Genmab; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Pharmacyclics; financial relationship (Professional Services) with BeiGene; financial relationship (Employment) with BMS; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with TG Therapeutics; financial relationship (Professional Services) with MorphoSys/Incyte.

Tanya Siddiqi, MD has a financial relationship (Independent contractor) with BMS; financial relationship (Independent contractor) with Astra Zeneca; financial relationship (Independent contractor) with Abbvie; financial relationship (Independent contractor) with Gilead/Kite; financial relationship (Independent contractor) with Beigene.

Chaitra Ujjani, MD has a financial relationship (Independent contractor) with AstraZeneca; financial relationship (Independent contractor) with Genentech; financial relationship (Independent contractor) with Eli Lilly; financial relationship (Independent contractor) with Atara; financial relationship (Independent contractor) with Abbvie; financial relationship (Independent contractor) with Beigene; financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with Incyte; financial relationship (Independent contractor) with Pharmacyclics; financial relationship (Independent contractor) with Epizyme.

Matthew Ulrickson, MD has a financial relationship (Independent contractor) with Bristol Meyers Squib; financial relationship (Independent contractor) with Gilead; financial relationship (Travel) with Miltenyi; financial relationship (Independent contractor) with Genetech; financial relationship (Independent contractor) with Stemline.

Important Information about Claiming CME for this activity:

If you participated in the course titled - Seattle Cellular Therapy Summit (SCTS): Patient-Centered Approach to Improve Outcomes from 8/04/2023 to 08/05/2023 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is recorded content from that course from 8/04/2023 to 08/05/2023. However, you can still enroll in this activity and review the contents as needed.

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians

 

Available Credit

  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is free for all.